RECIP Criteria

Day 1 at EANM 2024 is underway, and we’re excited to be here in Hamburg! Our RECIP Criteria booth is all set, and it’s been a fantastic start. We’ve had inspiring conversations about the future of Next-Generation Treatment Response Evaluation in Prostate Cancer. One special highlight of the day: we welcomed our youngest visitor! Meet the future of nuclear medicine—already showing interest in what could be his future career. Could he be our “Next-Generation Nuclear Medicine Physician”? Time will tell, but it’s amazing to see such early enthusiasm. If you’re attending #EANM24, stop by and chat with us about the latest developments in PSMA-PET/CT response evaluation. The excitement is just beginning, and we can’t wait for the rest of the congress! #EANM2024 #RECIPCriteria

The clinical role of tumor volume expressing PSMA, segmentation tools, RECIP criteria for the evaluation of response to taxane-based therapies, how to select patients for RLT: these are the topics of our talk in Hamburg!!! Thanks to Hermes Medical Solutions for the possibility to talk about our projects on #prostatecancerpatients in collaboration with IEO Istituto Europeo di Oncologia and John Hopkins University. #eanm24 #theranostic #PSMA RECIP Criteria Francesco Ceci

𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗘𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗱𝘂𝗿𝗶𝗻𝗴 𝗥𝗮𝗱𝗶𝘂𝗺-𝟮𝟮𝟯 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗨𝘀𝗶𝗻𝗴 𝗣𝗦𝗠𝗔-𝗣𝗘𝗧/𝗖𝗧 𝙆𝙚𝙮 𝙄𝙣𝙨𝙞𝙜𝙝𝙩: PSMA-PET/CT performed after 3 cycles of Radium-223 therapy is prognostic for overall survival. Pairs of baseline and post-therapy PSMA-PET/CT scans, interpreted according to RECIP 1.0 and PPP criteria, were associated with overall survival (C-index: 0.66 vs. 0.63). 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙄𝙢𝙥𝙡𝙚𝙢𝙚𝙣𝙩𝙖𝙩𝙞𝙤𝙣: PSMA-PET/CT imaging can effectively evaluate treatment response in patients with metastatic castration-resistant prostate cancer undergoing Radium-223. Interpretation of PSMA-PET/CT images using RECIP 1.0 demonstrated better performance compared to PPP criteria. 𝘿𝙞𝙨𝙘𝙤𝙫𝙚𝙧 𝙢𝙤𝙧𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚: https://lnkd.in/ewAD-uY6 Qaid Shagera, MD, PhD | Carlos Artigas #PSMA #RECIP

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 𝗶𝗻 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀! A comprehensive meta-analysis on the dosimetry of 177Lu-PSMA radiopharmaceutical therapies has been published. 𝗞𝗲𝘆 𝗶𝗻𝘀𝗶𝗴𝗵𝘁: The meta-analysis included 29 studies and 535 patients. No significant difference was observed between absorbed doses of 177Lu-PSMA-I&T and 177Lu-PSMA-617. Notably, the research revealed very high heterogeneity among dosimetry methodologies used among studies. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁: 177Lu-PSMA-I&T and 177Lu-PSMA-617 may have similar antitumor activity and safety profile. Most importantly, standardisation of dosimetry methodology is required prior to clinical implementation. 𝙍𝙚𝙖𝙙 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚 𝙝𝙚𝙧𝙚: https://lnkd.in/d4K5cGgA Zachary Ells | Johannes Czernin | Jeremie Calais Society of Nuclear Medicine and Molecular Imaging (SNMMI) David Geffen School of Medicine at UCLA #PSMA #Theranostics #Dosimetry

𝗖𝗵𝗮𝗻𝗴𝗲 𝗶𝗻 𝗧𝗼𝘁𝗮𝗹 𝗟𝗲𝘀𝗶𝗼𝗻 𝗣𝗦𝗠𝗔 𝗱𝘂𝗿𝗶𝗻𝗴 [𝟭𝟳𝟳𝗟𝘂]𝗟𝘂-𝗣𝗦𝗠𝗔-𝟲𝟭𝟳 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝘀 𝗢𝘃𝗲𝗿𝗮𝗹𝗹 𝗦𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁: Changes in total activity of PSMA radiotracer (TLP) on PET/CT imaging during 177Lu-PSMA-617 are associated with overall survival. However, the prognostic value is decreasing when changes in TLP are combined with occurrence of new lesions. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁: When calculating #RECIP 1.0 criteria, investigators should incorporate changes in total tumor volume, as originally proposed, rather than changes in total activity of PSMA radiotracer. 𝗧𝗮𝗸𝗲 𝗵𝗼𝗺𝗲 𝗺𝗲𝘀𝘀𝗮𝗴𝗲: For response evaluation in prostate cancer using PSMA-PET imaging, it is important to differentiate between tumor burden parameters such as 𝘵𝘰𝘵𝘢𝘭 𝘵𝘶𝘮𝘰𝘳 𝘷𝘰𝘭𝘶𝘮𝘦 and 𝘵𝘰𝘵𝘢𝘭 𝘭𝘦𝘴𝘪𝘰𝘯 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺. Comparison of their prognostic value in the same patient cohort is awaited to provide more insights. 𝘿𝙞𝙨𝙘𝙤𝙫𝙚𝙧 𝙢𝙤𝙧𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚: https://lnkd.in/d8aCa4MH Caroline Burgard | Samer Ezziddin | Florian Rosar #ProstateCancer #PSMA #Radiology #NuclearMedicine

𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝘂𝘀𝗶𝗻𝗴 𝘀𝗮𝗺𝗲-𝗱𝗮𝘆 𝗽𝗼𝘀𝘁-𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗦𝗣𝗘𝗖𝗧/𝗖𝗧 𝗶𝘀 𝗮𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝘄𝗶𝘁𝗵 𝗼𝘂𝘁𝗰𝗼𝗺𝗲 𝗮𝗳𝘁𝗲𝗿 𝟭𝟳𝟳𝗟𝘂-𝗣𝗦𝗠𝗔-𝟲𝟭𝟳. 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁: RECIP-like changes in tumor volume (a decrease of over 30%) observed on same-day post-therapy SPECT/CT are linked to significantly shorter overall survival (NR vs. 10 months) and progression-free survival (6 months vs. 1 month) following 177Lu-PSMA-617. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Post-therapy SPECT/CT imaging performed 1–2 hours after 177Lu-PSMA-617 administration showed potential for assessing treatment response effectively. However, small new lesions may be missed. 𝘿𝙞𝙨𝙘𝙤𝙫𝙚𝙧 𝙢𝙤𝙧𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙛𝙪𝙡𝙡 𝙖𝙧𝙩𝙞𝙘𝙡𝙚: https://lnkd.in/d5hbH53e Andrei Iagaru | Sandy Srinivas | Hong Song

𝗟𝗼𝗻𝗴 𝗮𝘄𝗮𝗶𝘁𝗲𝗱 𝗱𝗮𝘁𝗮 𝗶𝗻 #𝗣𝗦𝗠𝗔 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗶𝘀 𝗳𝗶𝗻𝗮𝗹𝗹𝘆 𝗼𝘂𝘁! Extended therapy with [177Lu]Lu-PSMA is safe and efficacious. Time to change gears and go beyond 6 cycles in selected patients. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗽𝗮𝗰𝘁: #RECIP 1.0 after 2 cycles of [177Lu]Lu-PSMA may inform whether an extended treatment is appropriate. Patients with RECIP-PR are better candidates for rechallenge treatment, while patients with RECIP-SD may benefit more from continuous treatment. 🔗 Check out the link and learn more about this research: https://lnkd.in/dy5Kvp7Z 𝗙𝘂𝘁𝘂𝗿𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵: FLEX-MRT and Re-LuPSMA trials at #UCLA Health from Dr. Jeremie Calais are investigating prospectively the safety of the extended protocol of 177Lu-PSMA-617. The Journal of Nuclear Medicine - JNM Priv.-Doz. Dr. Robert Seifert, Matthias Eiber, Ken Herrmann, Constantin Lapa, Prof. Dr. med. Kambiz Rahbar, Wolfgang P. Fendler

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄𝘀 𝗶𝗻 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵! #RECIP 1.0 after 2 cycles of 177Lu-PSMA-617 is associated with progression-free survival in mCRPC! Median progression-free survival in RECIP-PD was only 2.5 months compared to 7.2 months in patients with RECIP-nonPD. 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁: PSMA-PET/CT evaluated by RECIP 1.0 can be used in earlier stages of prostate cancer to evaluate drug efficacy and predict progression-free survival. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Visual RECIP 1.0 can be calculated by physicians to identify tumor progression on PSMA-PET/CT, ready for clinical practice. 🔗 Check out the article to learn more: https://lnkd.in/eFm_wRz7 #JNM #PSMA The Journal of Nuclear Medicine - JNM Andrei Gafita, Loïc Djaïleb, Matthias Eiber, Jeremie Calais, Ken Herrmann, Andrea Farolfi

Exciting Update in Medical Imaging! RECIP 1.0 is advancing! Traditionally assessed visually by physicians or quantitatively using tumor segmentation software, RECIP 1.0 can now be calculated fully automatically to evaluate treatment response in prostate cancer using PSMA-PET/CT. aPROMISE by #EXINI, an AI-based platform that enables tumor quantification. aPROMISE can automatically calculate RECIP 1.0 (aRECIP) with high accuracy.   Preliminary data presented at ASCO GU '24 showed a 92.5% agreement between manual evaluation of RECIP and automatic RECIP! 🔗 Check out aPROMISE here: https://lnkd.in/d3v-MDfx #RECIPCriteria #aPROMISE #ProstateCancer #NuclearMedicine #Radiology #PSMA #ArtificialIntelligence #Innovation #Oncology

Want to know more about the RECIP Criteria? and how to use it? 🤔 Register to join this webinar and change your clinical practice ! February the 15th at 12:00 PM EST / 06:00 PM CET #prostatecancer #ai #biomarkers